Facebook
  1. Home
  2. News & Events
  3. In the News

In the News

ICON experts frequently author or contribute to industry trade press.

Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.

  • firstword-logo

    Expert Q&A: The impact of the clinical trial liaison function

    Expert Q&A: The impact of the clinical trial liaison function

    The clinical trial liaison (CTL) function was first introduced in 2014 to help sponsors differentiate themselves from the competition by driving recruitment success in clinical trials.

    FirstWord spoke with Elizabeth Pash, Senior Director of Global Site Engagement Operations at ICON, to find out exactly what this relatively new role involves, its value in developing and delivering optimal clinical trials and how it is set to evolve in future.

    Summary points from the interview:

    • In the competitive world of pharmaceutical research, sponsors can differentiate themselves by driving recruitment success in clinical trials.
    • The CTL role was introduced in 2014 to bring doctorate-trained clinical research professionals into the clinical trial process to support site identification, activation and recruitment, ensuring optimal productivity of clinical trials.
    • While CTLs and clinical research associates (CRAs) are both considered protocol experts and build relationships with sites, CTLs focus on the scientific aspects of a protocol rather than the eligibility criteria and schedule of assessments.
    • At ICON, CTLs have contributed to a 20% boost in the targeted recruitment rate and helped approximately 70% of sites achieve their baseline recruitment goals. In the past five years, they have also helped sponsors bring nine new compounds to market and receive two new indication approvals for already-approved medications.
    • As more clinical trials begin to incorporate more decentralised approaches, the need for roles like CTLs is set to steadily increase across the industry.
    • Potential is increasing for CTLs to establish partnerships earlier with sponsors, supporting trial and protocol design, conducting targeted investigator interviews and applying the information in the early stages of clinical development.

    [Subscription is required to view the entire interview]

  • PM-Live-Thumbnail

    Rare disease drug development

    In this article, Will Maier outlines the importance of utilising real world evidence from rare diseases in accelerating product approval and development.

  • PM-Live-Thumbnail

    CAR-T cell therapy in oncology

  • IPI-thumbnail

    The Use of Predictive Analytics to Improve Quality in Clinical Trials Quality Assurance

    Rose Kidd, Executive Vice President, Quality and Compliance at ICON, discusses how predictive analytics provide a real opportunity to develop new and innovative processes in the area of QA.

    This article is taken from International Pharmaceutical Industry, Volume 14, Issue 3, pages 32-33. Senglobal Ltd

  • ipt_thumbnail_170x170-(1)

    Providing support throughout the patient journey

    Concierge services are critical to helping patients navigate technology and other logistics in a decentralised clinical trial. Laney Preheim outlines how they can best be implemented.

    This article is taken fromInnovations in Pharmaceutical Technology, October 2022, pages 34-36 . Samedan Ltd

  • contract-pharma

    Anthrax vaccine clinical trial

    This news article, first published on Contract Pharma.com, outlines how ICON has been selected by BARDA to execute an anthrax vaccine clinical trial.

  • EPR-Logo-Thumbnail-(1)

    Using RWE in rare disease drug development: effective innovations with historical controls

    With a growing number of therapies under development for rare diseases, William Maier discusses how real-world evidence can be effectively used as a historical control, overcoming challenges presented in clinical development.

  • 13175-065-Clinical-Trials-Arena-Thumbnail

    Robotic Process Automation: Recruiting bots to accelerate clinical trials

    Ronan Fox, Senior Vice President of Applied Digital Solutions, contributes his views on the increasing use of RPA in clinical trials.

  • applied-clinical-trials

    Redefining CRO sourcing model terminology to optimise outsourcing strategies

    Samir Shah, President, Strategic Solutions at ICON contributes to this Applied Clinical Trials article discussing the compelling need for new terminology for sourcing models in the CRO industry.

    Reprinted with permission from Applied Clinical Trials. Applied Clinical Trials is a copyrighted publication of MultiMedia Healthcare, LLC. All rights reserved.

  • pm360

    Embedding the patient point of view in everything you do

    Rachel Ballinger, Patient Centred Outcomes Principal, shares the importance of using positive language when speaking with study participants.